SCHEDULE 13D: Major Shareholder Discloses Significant Stake and Strategic Agreements in OS Therapies Inc.
Beneficial Ownership Disclosure
Shalom Auerbach and Einodmil LLC have filed a Schedule 13D, revealing beneficial ownership of 11.9% and 11.8% respectively in OS Therapies Incorporated, detailing share acquisitions through note conversions and a strategic transfer agreement tied to the company's IPO.
Summary
- Shalom Auerbach and Einodmil LLC, collectively 'Reporting Persons,' have filed a Schedule 13D regarding their beneficial ownership in OS Therapies Incorporated (Issuer).
- As of the filing date, Shalom Auerbach beneficially owns 2,554,582 shares, representing 11.9% of the Issuer's outstanding common stock.
- Einodmil LLC beneficially owns 2,531,211 shares, representing 11.8% of the Issuer's outstanding common stock.
- The shares were acquired through the conversion of promissory notes: Einodmil converted $3,270,000 in notes for 1,743,556 shares, and Mr. Auerbach converted $25,000 in notes for 23,371 shares on August 2, 2024.
- Prior to the Issuer's IPO on July 31, 2024, Einodmil held 804,375 shares, including 600,000 shares from a Transfer Agreement and 204,375 shares from private placements.
- On January 15, 2025, Einodmil sold 16,720 shares for approximately $112,600.
- The Reporting Persons state their ability to control and influence the Issuer's corporate activities as substantial owners.
- Einodmil entered into a Transfer Agreement on May 13, 2024, with Paul Romness (CEO of OS Therapies), receiving 600,000 shares immediately and potentially up to 600,000 additional shares contingent on the stock's average VWAP 20 trading days after the 6-month lockup period expires.
Sentiment
Score: 7
Explanation: The filing indicates a significant, strategic investment by the reporting persons, including participation in the IPO and conversion of substantial debt into equity. While there was a small sale, the overall picture is one of a committed, influential shareholder. The contingent share transfer mechanism, however, suggests a hedging strategy by the CEO against potential post-lockup price declines, which introduces a slight negative nuance regarding the CEO's confidence in the stock's immediate future performance.
Positives
- Reporting Persons have accumulated a significant stake (over 11% each), indicating a strong belief in the company's long-term prospects.
- The Transfer Agreement incentivized Einodmil to enter a lock-up agreement, facilitating the Issuer's IPO.
Negatives
- Einodmil sold 16,720 shares for approximately $112,600 on January 15, 2025, which could be perceived as a slight reduction in their stake or a liquidity event.
- The contingent transfer of additional shares from Paul Romness to Einodmil is inversely related to the stock price performance post-lockup, meaning Einodmil receives more shares if the price is lower, which could be seen as a negative outlook on the stock's future performance by the CEO.
Risks
- The number of additional shares Einodmil may receive from the Transfer Agreement is contingent on future stock price performance (average VWAP 20 trading days post-lockup expiration), which is beyond the Reporting Persons' control.
- The Reporting Persons, as substantial owners, may be able to control the Issuer's business and influence corporate activities, which could be a risk for other shareholders if their interests diverge.
Future Outlook
The Reporting Persons may, from time to time, acquire additional shares of Common Stock and/or retain and/or sell all or a portion of their holdings in the open market or privately negotiated transactions. Any future actions will depend on factors such as the Common Stock's price levels, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects, alternative investment opportunities, and liquidity needs. The Transfer Agreement also outlines a future contingent transfer of up to 600,000 shares to Einodmil based on the stock's VWAP after the 6-month lockup period expires.
Industry Context
This filing indicates a significant ownership stake in OS Therapies Incorporated, a company that recently completed an IPO. The involvement of a lock-up agreement and contingent share transfers tied to post-lockup stock performance suggests a focus on the initial public offering and the subsequent market performance of the newly public company. The company operates in the therapeutics industry, which often involves substantial capital requirements and long development cycles, making early investor confidence and strategic agreements crucial.
Related Party Transactions
- The Transfer Agreement, dated May 13, 2024, between Einodmil LLC and Paul Romness, who is the CEO and a significant shareholder of OS Therapies Incorporated. This agreement involved Paul Romness transferring shares to Einodmil in exchange for Einodmil entering into a lock-up agreement to facilitate the company's IPO.
Stakeholder Impact
- Shareholders: The significant beneficial ownership by Shalom Auerbach and Einodmil LLC could lead to increased shareholder influence and potential control over corporate activities. The contingent share transfer mechanism could impact the perceived value or future dilution for existing shareholders depending on the stock's post-lockup performance.
- Management: The Transfer Agreement with CEO Paul Romness highlights his direct involvement in facilitating the IPO and managing relationships with key investors.
Next Steps
- Potential future acquisitions or dispositions of Common Stock by the Reporting Persons based on market conditions and Issuer's performance.
- Potential additional transfer of up to 600,000 shares from Paul Romness to Einodmil based on the average VWAP of OS Therapies' stock 20 trading days following the expiration of the 6-month lockup period.
Key Dates
| Date | Description |
|---|---|
| 2022-11-01 | Start of period for Issuer's private placements where Einodmil acquired 204,375 shares (post-split basis) as noteholders. |
| 2023-03-10 | Date Einodmil entered into a Convertible Note Purchase Agreement with OS Therapies Incorporated. |
| 2023-03-13 | Date of the related Unsecured Convertible Promissory Note. |
| 2024-04-30 | End of period for Issuer's private placements where Einodmil acquired 204,375 shares (post-split basis) as noteholders. |
| 2024-05-13 | Effective date of the Transfer Agreement between Einodmil LLC and Paul Romness. |
| 2024-07-31 | Date of the event requiring the filing of this statement; Issuer's initial public offering (IPO) date. |
| 2024-08-01 | Date Issuer's Rule 424(b)(4) Prospectus was filed with the SEC. |
| 2024-08-02 | Date of Note Conversions, where Einodmil was issued 1,743,556 shares and Mr. Auerbach was issued 23,371 shares. |
| 2024-12-31 | Date as of which 21,533,355 shares of Common Stock were reported as outstanding in the Issuer's Registration Statement on Form S-1/A. |
| 2025-01-03 | Date Issuer's Registration Statement on Form S-1/A was filed with the SEC. |
| 2025-01-15 | Date Einodmil sold 16,720 shares of Common Stock. |
| 2025-01-17 | Date the Joint Filing Agreement was signed and the Schedule 13D was filed. |
Keywords
OS Therapies Incorporated, Schedule 13D, Shalom Auerbach, Einodmil LLC, Beneficial Ownership, Common Stock, SEC Filing, Note Conversion, Initial Public Offering, IPO, Transfer Agreement, Lock-up Agreement, Shareholder Influence, Equity Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.